Intas And mAbxience Strike Global Etanercept Deal

Licensing Agreement For Enbrel Biosimilar Candidate Covers More Than 150 Countries

 
• By Dave Wallace

Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.

electronically connected globe (shutterstock)
The agreement covers 150+ markets around the world • Source: Shutterstock

More from Deals

More from Business